Novavax, Inc.

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP

670002401
SEDOL

BK92FW3
CIK

0001000694

www.novavax.com
LEI: 529900J4GJHPEPQ23205
Novavax is a Member of Themefolio
          Covid19-STX          
          Nano-Technology          
FIGI: BBG000N2H7S5
NVAX

Novavax, Inc.
GICS: - · Sector: Healthcare · Sub-Sector: Biotechnology
AI
PROFILER
NAME
Novavax, Inc.
ISIN
US6700024010
TICKER
NVAX
MIC
XNAS
REUTERS
NVAX.OQ
BLOOMBERG
NVAX US
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants

The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by PR-Newswire.

Tue, 11.03.2025       Novavax
US6700024010

James Young, PhD retires as Chair of the Board, Margaret McGlynn, RPh, appointedJohn Shiver, PhD appointed to board of directors

GAITHERSBURG, Md., March 11, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that James Young, PhD, is retiring as Chair of the Board and Margaret McGlynn, RPh, has been appointed as his successor. The Company also appointed John Shiver, PhD, to its board as an independent director.

Thu, 27.02.2025       Novavax
US6700024010

GAITHERSBURG, Md., Feb. 27, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), today announced that the management team will participate in the following upcoming investor conferences:

TD Cowen 45th Annual Health Care Conference:

Fireside Chat

Date:

Tuesday, March 4, 2025

Time:

9:10 – 9:40 a.m. Eastern Time (ET)

Location:

Boston, MA

 

Conference

Event:

Investor Meetings

Date:

Tuesday, March 4, 2025

Leerink Partners 2025 Global Healthcare Conference:

Presentation

Date:

Tuesday, March 11, 2025

Time:

3:40 – 4:10 p.m. ET

Location:

Miami Beach, FL

 

Conference

Event:

Investor Meetings

Date:

Tuesday, March 11, 2025

Jefferies Biotech on the Beach Summit:

Conference

Event:

Investor Meetings

Date:

Wednesday, March 12, 2025

Location:

 

Miami Beach, FL

Thu, 27.02.2025       Novavax
US6700024010

Transitioned lead commercial responsibility of Nuvaxovid™ COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in the fourth quarter of 2024 and $682 million for the full year 2024 Achieved $50 million milestone under Sanofi agreement associated with the pediatric clinical trial database lock for the first cohortCompleted $200 million sale of Czech Republic manufacturing facility to Novo Nordisk; reduces annual costs by approximately $80 millionAdvanced pipeline programs, based on proven and innovative technology platformEnded full year 2024 with over $1 billion in Cash and accounts receivablesProvides 2025 financial guidance and revenue framework Company to host conference call today at 8:30 a.m. ET
Thu, 20.02.2025       Novavax
US6700024010

GAITHERSBURG, Md., Feb. 20, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, February 27, 2025. Details of the event and replay are as follows:

Conference call details:

Date:

February 27, 2025

Time:

8:30 a.m. U.S. ET

URL to register phone:

https://emportal.ink/3PsP11e

Dial-in number:

(800) 836-8184 (Domestic) or

(+1) (646) 357-8785 (International)

Webcast:

  ir.novavax.com/events

Fri, 13.12.2024       Novavax
US6700024010

Novavax continues to progress Sanofi agreement by achieving first milestone, with additional milestones and ongoing tiered royalties to come, solidifying a strong model for future partnershipsNovavax's COVID-19 vaccine included in Sanofi's two combination vaccine candidates for prevention of influenza and COVID-19, for which Phase 1/2 trials were initiated and Fast Track designation recently granted in the U.S.

GAITHERSBURG, Md., Dec. 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through its partnership with Sanofi. The Company has achieved a milestone associated with its Phase 2/3 clinical trial for its COVID-19 vaccine in children, triggering the first $50 million milestone payment from Sanofi.

Tue, 10.12.2024       Novavax
US6700024010

Company continuing to work with the U.S. FDA on potential for accelerated approval pathwayNovavax intends to partner on both candidates to advance to filing and commercialization

GAITHERSBURG, Md., Dec. 10, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the first participants have been dosed in its COVID-19-Influenza Combination (CIC) and stand-alone seasonal influenza Phase 3 trial. The trial will evaluate the immunogenicity and safety of the CIC and stand-alone seasonal influenza vaccine candidates compared to Novavax's updated 2024-2025 COVID-19 vaccine (NVX-CoV2705) and a licensed seasonal influenza vaccine comparator in adults aged 65 and older.

Wed, 04.12.2024       Novavax
US6700024010

Agreement provides significant, non-dilutive capital to Novavax, further enabling the Company to advance its corporate growth strategy of driving value from its pipeline assets and proven technology platformProvides Novavax with $190 million cash payment in 2024 and additional $10 million in 2025, and annual operating cost reductions of approximately $80 million

GAITHERSBURG, Md., Dec. 4, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it has signed a definitive agreement to sell its manufacturing facility in Bohumil, Czech Republic to Novo Nordisk for $200 million. The agreement includes a transfer of assets, including a 150,000-square foot state-of-the-art recombinant protein manufacturing facility with support buildings, along with the existing workforce and all related and required infrastructure.

Tue, 19.11.2024       Novavax
US6700024010

NEW YORK, Nov. 18, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ: NVAX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.  

The investigation concerns whether Novavax and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

Fri, 15.11.2024       Novavax
US6700024010

GAITHERSBURG, Md., Nov. 15, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Company granted a non- qualified stock option and restricted stock units to Ruxandra Draghia-Akli, MD, PhD, its newly appointed Executive Vice President and Head of Research & Development, as a material inducement for her entry into employment with Novavax, effective as of November 11, 2024 (the "grant date"). These awards were approved by the Compensation Committee of Novavax and were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Novavax, Inc. 2023 Inducement Plan.

Wed, 13.11.2024       Novavax
US6700024010

GAITHERSBURG, Md., Nov. 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the Jefferies London Healthcare Conference.

Conference Details:

Fireside Chat

Date:

Wednesday, November 20, 2024

Time:

11:00 – 11:25 a.m. Greenwich Mean Time

Location:

London, United Kingdom

Moderator:

Roger Song, MD, CFA, Equity Analyst

Novavax participants:

John C. Jacobs, President and Chief Executive Officer and Additional Management Team Members

Investor Meetings

Date:

Wednesday, November 20, 2024

We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S